Clinical Lab Products
  • Diagnostic Technologies
    • Anatomic Pathology
    • Clinical Chemistry
    • Digital Pathology
    • Flow Cytometry
    • Hematology & Serology
    • Immunoassay
    • Mass Spectrometry
    • Microbiology
    • Molecular Diagnostics
    • Point-of-Care
    • Urinalysis & Toxicology
  • Lab Products
    • Biochemicals & Chemical Reagents
    • Information Technology
    • Lab Automation
    • Lab Equipment
    • Lab Safety
    • Labware & Consumables
    • Quality Systems
  • Disease States
    • Allergy & Autoimmune
    • Cancer
    • Cardiovascular
    • Cerebrovascular
    • Dementias & Alzheimer’s
    • Diabetes & Metabolic Diseases
    • Infectious Diseases
    • Kidney Disease
    • Respiratory Disease
    • Sepsis
    • Womens Health
  • Lab Management
    • Accreditation
    • Company News
    • Compliance
    • Proficiency Testing
    • Resource Center
  • Resources
    • Podcasts
    • Webcasts
    • White Papers
    • Videos
  • Edition Archive

Select Page

Tag: National Comprehensive Cancer Network

All

Latest
NCCN Guidelines Add ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

NCCN Guidelines Add ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

Foresight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.

  • NCCN Genetic Testing Guidelines Expanded for High-Risk Cancer Assessment

  • Universal Hereditary Cancer Genetic Testing Breast Cancer Improves Patient Outcomes

  • African American Breast Cancer Patients Less Likely to Receive Genetic Counseling, Testing

  • Cancer Patients Need Access to Genetic Testing to Improve Treatment

  • Myriad: NCCN Updates Professional Guidelines for Patients with Prostate Cancer

  • Navify Guidelines App Offers Clinicians Guidance for Patients with Common Cancers

  • From the Editor: An Opportune Moment

  • Determining Molecular Response in Chronic Myeloid Leukemia

  • NCCN Guidelines Endorse Biomarker Testing for Prostate Cancer

All

Latest
NCCN Guidelines Recommend VeriStrat Testing for NSCLC

NCCN Guidelines Recommend VeriStrat Testing for NSCLC

Biodesix recently announced the inclusion of its VeriStrat profiling test in updated evidence-based, consensus-driven NCCN Guidelines for managing non-small-cell lung cancer.

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found

Clinical Lab Products

7300 W 110th St – Floor 7
Overland Park, KS 66210
(913) 955-2600

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Press Releases

Key Resources

Podcasts

Webinars

White Papers

Videos

Helpful Links

Media Solutions Kit

Subscribe Now

Contact Us

Submit an Article

  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2024 MEDQOR LLC. All Rights Reserved

✖